全文获取类型
收费全文 | 3308篇 |
免费 | 140篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 52篇 |
妇产科学 | 29篇 |
基础医学 | 548篇 |
口腔科学 | 44篇 |
临床医学 | 239篇 |
内科学 | 779篇 |
皮肤病学 | 244篇 |
神经病学 | 356篇 |
特种医学 | 183篇 |
外国民族医学 | 4篇 |
外科学 | 408篇 |
综合类 | 13篇 |
预防医学 | 121篇 |
眼科学 | 40篇 |
药学 | 172篇 |
中国医学 | 7篇 |
肿瘤学 | 230篇 |
出版年
2023年 | 7篇 |
2022年 | 26篇 |
2021年 | 47篇 |
2020年 | 28篇 |
2019年 | 36篇 |
2018年 | 40篇 |
2017年 | 41篇 |
2016年 | 47篇 |
2015年 | 74篇 |
2014年 | 90篇 |
2013年 | 140篇 |
2012年 | 181篇 |
2011年 | 175篇 |
2010年 | 116篇 |
2009年 | 124篇 |
2008年 | 240篇 |
2007年 | 244篇 |
2006年 | 240篇 |
2005年 | 207篇 |
2004年 | 205篇 |
2003年 | 235篇 |
2002年 | 187篇 |
2001年 | 59篇 |
2000年 | 53篇 |
1999年 | 55篇 |
1998年 | 55篇 |
1997年 | 43篇 |
1996年 | 29篇 |
1995年 | 40篇 |
1994年 | 16篇 |
1993年 | 25篇 |
1992年 | 15篇 |
1991年 | 25篇 |
1990年 | 18篇 |
1989年 | 19篇 |
1988年 | 15篇 |
1987年 | 19篇 |
1986年 | 23篇 |
1985年 | 13篇 |
1984年 | 7篇 |
1983年 | 13篇 |
1982年 | 18篇 |
1980年 | 8篇 |
1979年 | 15篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1976年 | 10篇 |
1975年 | 7篇 |
1970年 | 13篇 |
1934年 | 6篇 |
排序方式: 共有3476条查询结果,搜索用时 15 毫秒
41.
42.
43.
Annette Paschen Mingxia Song Wolfram Osen Xuan Duc Nguyen Jan Mueller-Berghaus Daniela Fink Nadine Daniel Mariel Donzeau Wolfgang Nagel Harald Kropshofer Dirk Schadendorf 《Clinical cancer research》2005,11(14):5241-5247
PURPOSE: The frequently expressed differentiation antigen tyrosinase-related protein-2 (TRP-2) has repeatedly been described as a target of spontaneous cytotoxic T-cell responses in melanoma patients, suggesting that it might be an ideal candidate antigen for T cell-based immunotherapy. As a prerequisite for immunization, T-cell epitopes have to be identified. Whereas a number of HLA class I-presented TRP-2-derived epitopes are known, information about HLA class II-presented antigenic ligands recognized by CD4+ T helper (Th) cells is limited. EXPERIMENTAL DESIGN: The search for TRP-2-derived Th epitopes was carried out by competitive in vitro peptide binding studies with predicted HLA-DRB1*0301 ligands in combination with peptide and protein immunizations of HLA-DRB1*0301 transgenic mice. In vivo selected candidate epitopes were subsequently verified for their immunogenicity in human T-cell cultures. RESULTS: This strategy led to the characterization of TRP-2(60-74) as an HLA-DRB1*0301-restricted Th epitope. Importantly, TRP-2(60-74)-reactive human CD4+ Th cell lines, specifically recognizing target cells loaded with recombinant TRP-2 protein, could be established by repeated peptide stimulation of peripheral blood lymphocytes from several HLA-DRB1*03+ melanoma patients. Even short-term peptide stimulation of patients' peripheral blood lymphocytes showed the presence of TRP-2(60-74)-reactive T cells, suggesting that these T cells were already activated in vivo. CONCLUSION: Peptide TRP-2(60-74) might be a useful tool for the improvement of immunotherapy and immune monitoring of melanoma patients. 相似文献
44.
Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells 总被引:1,自引:0,他引:1
Sponring A Filipiak W Ager C Schubert J Miekisch W Amann A Troppmair J 《Cancer biomarkers : section A of Disease markers》2010,7(3):153-161
Analysis of volatile organic compounds (VOCs) provides an elegant approach for cancer screening and disease monitoring, whose use is currently limited by a lack of validated cancer-derived metabolites, which may serve as biomarkers. The aim of the experiments presented here was to investigate the release and consumption of VOCs from the non small cell lung cancer cell line NCI-H1666, which was originally derived from a bronchoalveolar carcinoma.Following detachment by trypsinization suspended cells were incubated in a sealed fermenter for 21 hours. 200 ml of headspace from the cell culture were sampled, diluted with dry, highly purified air and preconcentrated by adsorption on three different solid sorbents with increasing adsorption strength. VOC-analysis was performed by thermodesorption-gas chromatography mass spectrometry (TD-GC-MS). In contrast to our previous studies experiments with NCI-H1666 cells only confirmed the consumption of several aldehydes, n-butyl acetate and the ethers methyl tert-butyl ether and ethyl tert-butyl ether, but no unequivocal release of VOCs was observed. Together with our previously published work these data indicate that the consumption of certain VOCs is commonly observed while their release shows cell line-restricted patterns, whose underlying causes are unknown. 相似文献
45.
Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction 下载免费PDF全文
Ines Gockel Leila Sisic Jolly Schmitz Nikolas H. Stoecklein Christiane Driemel Birte Möhlendick Thomas Schmidt Wolfram T. Knoefel Hauke Lang Reinhard Büttner Daniel Vallböhmer 《International journal of cancer. Journal international du cancer》2015,137(1):230-237
Neoadjuvant multimodality treatment is frequently applied to improve the poor prognosis of locally advanced adenocarcinomas of the gastroesophageal junction. This study aimed to asses if serum microRNA profiles are useable as response indicators in this therapeutic setting. Fifty patients with locally advanced adenocarcinomas of the gastroesophageal junction were included in the study. All patients received neoadjuvant therapy and subsequently underwent surgical resection. Histomorphologic regression was defined as major histopathological response when resected specimens contained less than 10% vital residual tumor cells. Circulating RNA was isolated from pretherapeutic/post‐neoadjuvant blood serum samples. RNA from nine patients was applied to PCR microarray analyses Based on these findings possible predictive miRNA markers were validated by quantitative RT‐PCR analyses. Depending on the histomorphologic regression, a differential serum microRNA profile was identified by microarray analyses. Based on the divergent miRNA pattern, miR‐21, miR‐192, miR‐222, miR‐302c, miR‐381 and miR‐549 were selected for further validation. During neoadjuvant therapy, there was a significant increase of miR 222 and miR‐549. Although on an expanded patient cohort, the six microRNAs could not be validated as markers for therapy response, there was a significant correlation between a high miR‐192 and miR‐222 expression with a high T‐category as well as miR‐302c and miR‐222 expression significantly correlated with overall survival. Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT‐PCR analyses a prognostic impact of miR‐222 and miR‐302c was detected. 相似文献
46.
Thorsten Zenz Markus Kreuz Maxi Fuge Wolfram Klapper Heike Horn Annette M. Staiger Doris Winter Hanne Helfrich Jennifer Huellein Martin‐Leo Hansmann Harald Stein Alfred Feller Peter M?ller Norbert Schmitz Lorenz Trümper Markus Loeffler Reiner Siebert Andreas Rosenwald German Ott Michael Pfreundschuh Stephan Stilgenbauer for the German High‐Grade Non‐Hodgkin Lymphoma Study Group 《International journal of cancer. Journal international du cancer》2017,141(7):1381-1388
TP53 is mutated in 20–25% of aggressive B‐cell lymphoma (B‐NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current risk models in aggressive B‐NHL, we investigated TP53 gene mutations within the RICOVER‐60 trial. Of 1,222 elderly patients (aged 61–80 years) enrolled in the study and randomized to six or eight cycles of CHOP‐14 with or without Rituximab (NCT00052936), 265 patients were analyzed for TP53 mutations. TP53 mutations were demonstrated in 63 of 265 patients (23.8%). TP53 mutation was associated with higher LDH (65% vs. 37%; p < 0.001), higher international prognostic index‐Scores (IPI 4/5 27% vs. 12%; p = 0.025) and B‐symptoms (41% vs. 24%; p = 0.011). Patients with TP53 mutation were less likely to obtain a complete remission CR/CRu (CR unconfirmed) 61.9% (mut) vs. 79.7% (wt) (p = 0.007). TP53 mutations were associated with decreased event‐free (EFS), progression‐free (PFS) and overall survival (OS) (median observation time of 40.2 months): the 3 year EFS, PFS and OS were 42% (vs. 60%; p = 0.012), 42% (vs. 67.5%; p < 0.001) and 50% (vs. 76%; p < 0.001) for the TP53 mutation group. In a Cox proportional hazard analysis adjusting for IPI‐factors and treatment arms, TP53 mutation was shown to be an independent predictor of EFS (HR 1.5), PFS (HR 2.0) and OS (HR 2.3; p < 0.001). TP53 mutations are independent predictors of survival in untreated patients with aggressive CD20+ lymphoma. TP53 mutations should be considered for risk models in DLBCL and strategies to improve outcome for patients with mutant TP53 must be developed. 相似文献
47.
Summary The wealth of structural information now available on thrombin, its precursors, its substrates and its inhibitors allows a rationalization of its many roles. -Thrombin exhibits an unusually deep and narrow active-site cleft, formed by loop insertions that are characteristic of thrombin. This canyon structure is one of the prime causes for the narrow specificity of thrombin. As a result of the conjunction of amino acid residues with similar properties such as charge or hydrophobicity, thrombin can be divided up into a number of functional regions. The apposition of the active site to a hydrophobic pocket (the apolar binding site) on one side and a basic patch (the fibrinogen recognition exosite) on the other allows for a fine-tuning of enzymatic activity, as seen for fibrinogen. These two sites are also optimally used by the leech-derived inhibitor hirudin, allowing the very tight binding observed; thrombin inhibition is effected by blocking access to the active site. Interactions with antithrombin III are tightened with the help of heparin, which binds to a second basic site (the heparin binding site). Non-proteolytic cellular properties are attributed to the rigid insertion loop at Tyr60A. The observed rigidity of the thrombin molecule in its complexes makes thrombin ideal for structure-based drug design. Thrombin can be inhibited either at the active site or at the fibrinogen recognition exosite, or both. Structural information shows that binding at the former is enhanced by good fit of aromatic moieties to the aryl and S2 binding sites (the apolar binding site). Binding at the fibrinogen recognition exosite is facilitated by negatively charged groups. The unpredictable nature of inhibitor binding underlines the importance of experimental monitoring of structures of thrombin inhibitors in the drug design process. 相似文献
48.
49.
50.
Paul Störchle Wolfram Müller Marietta Sengeis Helmut Ahammer Alfred Fürhapter-Rieger Norbert Bachl Sonja Lackner Sabrina Mörkl Sandra Holasek 《Ultrasound in medicine & biology》2017,43(2):427-438
A recently standardized ultrasound technique for measuring subcutaneous adipose tissue (SAT) was applied to normal-weight, overweight and obese persons. Eight measurement sites were used: upper abdomen, lower abdomen, erector spinae, distal triceps, brachioradialis, lateral thigh, front thigh and medial calf. Fat compression was avoided. Fat patterning in 38 participants (body mass index: 18.6–40.3 kgm?2; SAT thickness sums from eight sites: 12–245 mm) was evaluated using a software specifically designed for semi-automatic multiple thickness measurements in SAT (sound speed: 1450 m/s) that also quantifies embedded fibrous structures. With respect to ultrasound intra-observer results, the correlation coefficient ρ = 0.999 (p < 0.01), standard error of the estimate = 1.1 mm and 95% of measurements were within ±2.2 mm. For the normal-weight subgroup, the median measurement deviation was 0.43 mm (1.1% of mean thickness), and for the obese/overweight subgroup it was 0.89 mm (0.5%). The eight sites used here are suggested to represent inter-individual differences in SAT patterning. High measurement accuracy and reliability can be obtained in all groups, from lean to overweight and obese, provided that measurers are trained appropriately. 相似文献